North America Stem Cell Umbilical Cord Blood Market - Industry Dynamics, Market Size, And Opportunity Forecast To 2027

The North America Stem Cell Umbilical Cord Blood Market is estimated to witness a rise in revenue from US$ 1,527.5 Mn in 2021 to US$ 3,828.3 Mn by 2027. The market is registering a CAGR of 16.5% during the forecast period 2022-2027. Stem cell therapy is one of the types of therapies that are being introduced for the betterment and advancement of healthcare sector and people around the world are turning to them and rejecting traditional regimens of drugs and hospital visits. The most common genetic disease treated is Severe Combined Immune Deficiency (SCID) followed by aplastic anemia. Cord blood has been extensively used for treatment of genetic diseases. It is one of three sources of blood stem cells that can repopulate a patient’s blood and immune system. Furthermore, the use of allogeneic hematopoietic stem cells (HSCs) to treat genetic blood cell diseases has become a clinical standard. Allogeneic hematopoietic cell transplantation (HCT) therapy is increasingly used for many patients with hematologic malignancies and other type of marrow failure or immune system disorders. 

The major factor responsible for the growth of the North America stem cell umbilical cord blood market includes increasing demand of genetic testing, fertility and reproduction assisted services and rise in spending capacity and suitable payment plans. The rising prevalence of genetic diseases such as autoimmune disease, cancer and diabetes has majorly augmented the demand for genetic testing in North America. Moreover, rise in spending capacity, suitable payment plans and significant increase in public investment for stem cell research further boost the market growth. Furthermore, the adoption of artificial intelligence and data science has provided ample of expansion opportunities to the market players. However, there are various ethical and legal issues related to cord blood stem cell research associated with the embryo. Also, identifiers or labeling of cord blood units provides yet another set of legal and ethical challenges in the marketplace.

Diseases treated by cord blood transfusion

Cancer

• Acute leukaemia
• Chronic leukaemia
• High-risk solid tumours
• Hodgkin and non-hodgkin lymphoma
• Myelodysplastic syndromes

Blood disorders

• Aplastic anaemia
• Beta thalassaemia
• Diamond-blackfan anaemia
• Fanconi anaemia
• Sickle cell disease

Immune disorders

• Chronic granulomatous disease
• Hystiocytic disorders
• Leukocyte adhesion deficiency
• Severe combined immunodeficiency diseases
• Wiskott-Aldrich syndrome

Metabolic disorders

• Krabbe disease
• Hurler syndrome
• Metachromatic leukodystrophy
• Sanfilippo syndrome

Report Summary

The study of the North America Stem Cell Umbilical Cord Blood Market considers various market determinants, industry value chain analysis and competitor analysis of the market. The report discusses the analysis of the stem cell umbilical cord blood industry for the period 2017-2027, where the base year is 2021 and the forecast period is 2022-2027. The report provides a detailed analysis of the North America Stem Cell Umbilical Cord Blood Market across 11 Chapters and 167 pages. The report includes data presentation across 19 tables and 43 statistical figures. 

The report provides PESTLE analysis, which is a tool to examine the external market environment factors that have an impact on the industry. The PESTLE analysis examines the Political, Economic, Social, Technological, Environmental and Legal factors in the external environment. Thus, sufficiently examining the threats and weaknesses of the industry. The research report also provides Porter’s five forces analysis wherein bargaining power of buyers is low and competitive rivalry is high. 

The subsequent section provides details of the market analysis based on different segments such as therapeutics, applications and country. The report includes detailed study of value chain of the industry. It includes laboratory requirements, processing and storage, distribution and end users. The report also covers extensively about the key competitors in the market for stem cell umbilical cord blood. 

Impact of COVID-19 on North America Stem Cell Umbilical Cord Blood Market 

COVID‐19 impacted industries with major hinderances in their businesses due to global shutdown activities to prevent the spread of virus. However, several markets particularly related to healthcare has flourished over time. In the past few years, stem cells have been proven to be an effective method to treat pulmonary disorders, including COVID-19. In addition, the prevailing scenario of COVID-19 is one of the factors driving the growth of the stem cell umbilical cord blood market in various regions. Stem cell therapy can be considered as a potential approach for the treatment of COVID-19 in the future. For instance, Lineage Cell Therapeutics received a grant of US$ 5 million from the California Institute for Regenerative Medicine (CIRM) to support the use of its allogeneic dendritic cell therapy for the development of a potential vaccine against SARS-CoV-2. 

Key Takeaways from the North America Stem Cell Umbilical Cord Blood Market Report

• Based on therapeutics, the immune disorders segment is anticipated to grow at the highest CAGR during the forecast period owing to high prevalence of inherited immune system disorders in North America. Moreover, the diabetes segment holds the highest share in the North America stem cell umbilical cord blood market in 2021 due to increasing research activities for using umbilical cord blood for the treatment of diabetes.
• In terms of applications, the regenerative medicine holds the significant share in the market in 2021 owing to major benefits offered by regenerative medicine. Moreover, the hematopoietic stem cell therapy segment is projected to grow at the highest CAGR in the market over forecast period. 
• Based on country, the U.S. dominates the stem cell umbilical cord blood market in 2021 due to the presence of major key players in the country. Whereas, Mexico is anticipated to project the highest CAGR in the North America market during the forecast period owing to the rising adoption of stem cell umbilical cord blood services in the country. 

Company Profile

• Advanced Cell Technology Inc. (ACT) is a biotechnology company that develops regenerative medicine solutions using stem cell technology. Moreover, the company is working towards the development of alternative methods for hESC derivation, hoping to conduct cloning without destroying embryos and therefore bypassing various ethical concerns. The company is working with regulatory agencies in the U.S. and Europe to commence multi-site Phase 2 clinical trials to further examine the efficacy and safety of its RPE cell therapy in patients suffering from SMD, as well as dry age-related macular degeneration (AMD).
• California Stem Cell (CSC) is a privately held corporation that specializes in the production of high-purity human cells for research and clinical applications. CSC has established proprietary technologies for scalable synthesis of human motor neurons, neural progenitors, cardiac muscle and sino-atrial node cells from hESCs since its inception in 2005. Moreover, the company can generate large quantities of differentiated human cells in an FDA-approved method, making these populations clinically useful.
• MEDIPOST is a leading global stem cell therapeutics organizations with the world’s first regulatory approved allogeneic human umbilical cord blood derived mesenchymal stem cell. The company is mainly operating through three segments, stem cell therapeutics, cord blood bank and nutritional supplements. The company’s mission is to help patients with incurable diseases and unravel unmet medical needs through stem cells and regenerative medicine through rigorous research, development and commercialization in the field of stem cell therapeutics.

Competitive Landscape

The key players in the North America Stem Cell Umbilical Cord Blood Market are Advanced Cell Technology, Inc., Americord Registry LLC, Athersys, Inc., California Stem Cell (CSC), CBR Systems, Inc., China Cord Blood Corporation (CCBC), Cord Blood America, Inc. (CBAI), Cordlife Group Limited, Cryo-Cell International, Inc., Cryoviva India, Sangamo Therapeutics, Inc., ExCellThera Inc., Geron Corporation, LifeCell International Pvt. Ltd., MEDIPOST, Magenta Therapeutics, Mesoblast Ltd, Cryo-Save, Opexa Therapeutics, Inc.,   Regrow Biosciences Pvt Ltd.,   Smart Cells International Ltd., Tacitus Therapeutics, Sino Biological and Teva Pharmaceuticals among others. Through extensive research, it is found that big players have adopted various competitive strategies such as mergers & acquisitions in order to have a grip of emerging market. Furthermore, leading companies are expanding their geographical boundaries by acquiring small brands and domestic companies.

Segmentation Overview 

North America Stem Cell Umbilical Cord Blood Market is segmented based on therapeutics, applications and country. The industry trends in the stem cell umbilical cord blood market are sub-divided into different categories in order to get a holistic view of the North America marketplace. 

Following are the different segments of the North America Stem Cell Umbilical Cord Blood Market:

By Therapeutics segment of the North America Stem Cell Umbilical Cord Blood Market is sub-segmented into:

• Cancer
• Diabetes
• Blood Diseases
• Immune Disorders
• Metabolic Disorders
• Bone Marrow Failure Syndrome
• Other Diseases

By Applications segment of the North America Stem Cell Umbilical Cord Blood Market is sub-segmented into:

• Transplant Medicine
• Regenerative Medicine
• Hematopoietic Stem Cell Therapy

By Country segment of the North America Stem Cell Umbilical Cord Blood Market is sub-segmented into:

• The U.S.
• Canada
• Mexico